<DOC>
	<DOCNO>NCT00463268</DOCNO>
	<brief_summary>The purpose study evaluate efficacy intermittent administration alendronate low dose , 70 mg every two week , osteoporosis prevention menopausal , osteopenic patient , n't want ca n't receive oestrogenic substitution treatment .</brief_summary>
	<brief_title>Osteoporosis Prevention With Low Dose Alendronate</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>45 60 yearold woman Menopausal since least 6 month Baseline lumbar BMD 1 till 2.5 Bone disease osteopenia Treatment selective estrogen receptor modulator ( SERMs ) , calcitonin hormone replacement therapy within 6 monts prior randomization Former current treatment bisphosphonate bone form agent Chronic use oral iv corticosteroid Any diagnosis malignancy le 12 month</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>osteopenia</keyword>
	<keyword>osteoporosis prevention</keyword>
	<keyword>alendronate</keyword>
</DOC>